APP debuts generic Zemuron in USA

APP Pharmaceuticals, a US manufacturer of multi-source and branded injectable pharmaceutical products, has launched rocuronium bromide  injection, the generic equivalent of Organon's Zemuron.

"In addition to safety measures such as bar-coding and latex-free  stoppers, APP has incorporated a peel off syringe label on all of its  rocuronium vials," said the firm's chief executive, Thomas Silberg.  "Adding this feature to the vials enables health care facilities to  comply with National Patient Safety Goal 3D, which requires labeling on  all medications, syringes for perioperative and other procedural  settings," he noted.

APP's rocuronium is AP-rated and preservative-free, and is marketed in  two dosage forms, 50mg/5mL and 100mg/10 mL. One of the most widely-used  muscle relaxants in the USA, Canada and many European countries,  according to IMS data, 2007 US sales of rocuronium were around $127.0  million, or 10 million units.